Alkermes plc. — insider transactions
15 transactions on record · CIK 1520262
Aggregates
computed from the filings belowPurchases, 12m
0
count of open-market buys
Sales, 12m
15
count of open-market sales
Buy / sell ratio, 12m
0.00
purchases per sale
Distinct insiders, 12m
5
Bought, 3m
$0
Sold, 3m
$5.3M
Median disclosure lag
0.0 d
trade date to filing date
Largest single trade, 24m
$2.2M
2026-08-03
Director share, 12m
46.7%
of transactions where role is stated
Current run
15 sells
consecutive same-direction transactions
Net 3m flow
-$5.3M
purchases minus sales
Total on record
15
Transactions
15 most recent shown| Disclosed | Traded | Lag, d | Insider | Role | Transaction | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-17 | 2026-08-17 | 0 | Nichols Christian Todd | SVP, Chief Commercial Officer | Open market sale | 664 | $49.65 | $33K | filing |
| 2026-08-17 | 2026-08-17 | 0 | Nichols Christian Todd | SVP, Chief Commercial Officer | Open market sale | 6,912 | $49.19 | $340K | filing |
| 2026-08-07 | 2026-08-05 | 2 | Jackson Blair Curtis | Director, CEO, Alkermes plc | Grant or award | 93,229 | $0.00 | — | filing |
| 2026-08-07 | 2026-08-05 | 2 | Jackson Blair Curtis | Director, CEO, Alkermes plc | Grant or award | 124,305 | $0.00 | — | filing |
| 2026-08-03 | 2026-08-03 | 0 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Exercise of derivative | 4,896 | $24.59 | $120.4K | filing |
| 2026-08-03 | 2026-08-03 | 0 | snyderman nancy lynn MD | Director | Exercise of derivative | 27,948 | $0.00 | — | filing |
| 2026-08-03 | 2026-08-03 | 0 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Exercise of derivative | 104 | $19.34 | $2K | filing |
| 2026-08-03 | 2026-08-03 | 0 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Exercise of derivative | 4,896 | $0.00 | — | filing |
| 2026-08-03 | 2026-08-03 | 0 | snyderman nancy lynn MD | Director | Open market sale | 44,472 | $50.35 | $2.2M | filing |
| 2026-08-03 | 2026-08-03 | 0 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Open market sale | 2,034 | $48.58 | $98.8K | filing |
| 2026-08-03 | 2026-08-03 | 0 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Open market sale | 9,000 | $48.58 | $437.2K | filing |
| 2026-08-03 | 2026-08-03 | 0 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Exercise of derivative | 104 | $0.00 | — | filing |
| 2026-08-03 | 2026-08-03 | 0 | snyderman nancy lynn MD | Director | Exercise of derivative | 27,948 | $46.72 | $1.3M | filing |
| 2026-08-03 | 2026-08-03 | 0 | snyderman nancy lynn MD | Director | Exercise of derivative | 16,524 | $46.72 | $772K | filing |
| 2026-08-03 | 2026-08-03 | 0 | snyderman nancy lynn MD | Director | Exercise of derivative | 16,524 | $0.00 | — | filing |